HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoshiki Nishizawa Selected Research

glutamyl- lysyl- alanyl- histidyl- aspartyl- glycyl- glycyl- arginine

2/2006Positive correlation of serum bio-intact PTH(1-84) but not intact PTH with parathyroid gland size in hemodialysis patients.
7/2005Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
5/2005Significance of Bio-intact PTH(1-84) assay in hemodialysis patients.
1/2004Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
10/2002Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoshiki Nishizawa Research Topics

Disease

29Chronic Kidney Failure (Chronic Renal Failure)
02/2022 - 09/2001
28Cardiovascular Diseases (Cardiovascular Disease)
03/2015 - 12/2002
27Atherosclerosis
02/2013 - 01/2002
25Type 2 Diabetes Mellitus (MODY)
06/2014 - 03/2002
20Osteoporosis
11/2019 - 01/2002
19Insulin Resistance
06/2014 - 06/2002
16Chronic Renal Insufficiency
07/2019 - 05/2003
16Bone Resorption
11/2014 - 01/2002
15Vascular Calcification
01/2014 - 07/2002
14Secondary Hyperparathyroidism
12/2018 - 12/2003
11Uremia
10/2012 - 03/2004
10Inflammation (Inflammations)
09/2013 - 01/2003
10Diabetes Mellitus
10/2012 - 06/2002
10Renal Insufficiency (Renal Failure)
01/2012 - 06/2002
9Hyperphosphatemia
07/2009 - 05/2004
7Body Weight (Weight, Body)
03/2013 - 09/2005
7Carotid Artery Diseases
01/2013 - 01/2005
7Primary Hyperparathyroidism
10/2007 - 02/2004
6Proteinuria
02/2022 - 12/2005
6Hypertension (High Blood Pressure)
02/2016 - 09/2004
6Coronary Artery Disease (Coronary Atherosclerosis)
08/2010 - 09/2002
5Postmenopausal Osteoporosis
01/2019 - 01/2003
5Dyslipidemias (Dyslipidemia)
02/2016 - 08/2006
5Hypercalcemia (Milk Alkali Syndrome)
01/2009 - 06/2002
4Nephrotic Syndrome (Syndrome, Nephrotic)
02/2022 - 10/2009
4Anemia
12/2016 - 05/2003
4Malnutrition (Nutritional Deficiencies)
04/2012 - 09/2004
4Neoplasms (Cancer)
06/2010 - 01/2006
4Osteomalacia
06/2010 - 01/2004
4Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2008 - 12/2005
4Hypothyroidism
02/2007 - 01/2005
3Fatigue
01/2015 - 04/2010
3Chronic Kidney Disease-Mineral and Bone Disorder (Renal Rickets)
11/2014 - 05/2005
3Obesity
01/2013 - 06/2002
3Peripheral Arterial Disease
12/2010 - 01/2005
3Hypophosphatemia
06/2010 - 01/2005
3Rheumatoid Arthritis
02/2010 - 12/2002
3Hypercholesterolemia
02/2010 - 01/2005
3Parathyroid Diseases (Parathyroid Disorders)
10/2009 - 10/2007
3Vascular System Injuries
03/2005 - 02/2004

Drug/Important Bio-Agent (IBA)

16Parathyroid Hormone (Parathormone)IBA
01/2014 - 06/2002
14Biomarkers (Surrogate Marker)IBA
01/2014 - 01/2004
13Vitamin DFDA LinkGeneric
12/2018 - 12/2003
12Glucose (Dextrose)FDA LinkGeneric
03/2015 - 07/2002
12Phosphates (Orthophosphate)IBA
03/2013 - 01/2005
11OsteocalcinIBA
01/2014 - 01/2003
11Insulin (Novolin)FDA Link
02/2013 - 07/2002
11AdiponectinIBA
02/2013 - 07/2004
11Indicators and Reagents (Reagents)IBA
02/2011 - 05/2003
10Alkaline PhosphataseIBA
11/2014 - 02/2005
10AlbuminsIBA
09/2013 - 09/2005
10C-Reactive ProteinIBA
10/2012 - 12/2002
9oxidized low density lipoproteinIBA
02/2022 - 12/2002
9deoxypyridinolineIBA
04/2006 - 10/2002
8CholesterolIBA
03/2015 - 05/2003
8CreatinineIBA
04/2014 - 05/2003
8Collagen Type I (Type I Collagen)IBA
01/2014 - 02/2005
8HDL CholesterolIBA
04/2010 - 06/2002
8LipidsIBA
02/2010 - 03/2002
7Fibroblast Growth Factor-23IBA
06/2010 - 01/2005
7MineralsIBA
07/2009 - 01/2005
7Triglycerides (Triacylglycerol)IBA
04/2009 - 01/2002
7pyridinolineIBA
02/2006 - 10/2002
6collagen type I trimeric cross-linked peptideIBA
01/2014 - 01/2004
6LDL CholesterolIBA
01/2012 - 01/2007
6alpha-2-HS-GlycoproteinIBA
08/2010 - 02/2006
6CalciumIBA
10/2007 - 01/2002
5Risedronic Acid (Actonel)FDA LinkGeneric
07/2019 - 12/2010
5Proteins (Proteins, Gene)FDA Link
03/2015 - 01/2006
5Serum AlbuminIBA
10/2012 - 05/2003
5Cholecalciferol (Vitamin D3)FDA Link
01/2010 - 01/2002
5glutamyl- lysyl- alanyl- histidyl- aspartyl- glycyl- glycyl- arginineIBA
02/2006 - 10/2002
4Diphosphonates (Bisphosphonates)IBA
07/2019 - 11/2006
4alfacalcidolIBA
12/2018 - 01/2002
4ErythropoietinFDA Link
12/2016 - 03/2007
4Tartrate-Resistant Acid PhosphataseIBA
11/2014 - 04/2007
4Pioglitazone (Actos)FDA Link
06/2014 - 06/2005
4Receptor for Advanced Glycation End ProductsIBA
02/2013 - 01/2007
4Advanced Glycation End ProductsIBA
04/2011 - 12/2005
4Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
03/2010 - 03/2007
4OsteoprotegerinIBA
02/2010 - 09/2002
4Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
02/2010 - 11/2004
4Cinacalcet (Sensipar)FDA Link
01/2010 - 10/2005
4Lipoproteins (Lipoprotein)IBA
12/2009 - 01/2002
4HDL LipoproteinsIBA
12/2009 - 06/2002
4Thyroxine (Levothyroxine)FDA LinkGeneric
12/2005 - 11/2003
3LDL Lipoproteins (beta Lipoproteins)IBA
02/2022 - 12/2009
3Calcitriol Receptors (Calcitriol Receptor)IBA
12/2018 - 01/2006
3Oxygen (Dioxygen)IBA
12/2010 - 01/2003
3Apolipoproteins E (ApoE)IBA
08/2010 - 05/2005
3IDL Lipoproteins (Lipoprotein, IDL)IBA
12/2009 - 01/2002
3Cyclin D1IBA
07/2009 - 10/2005
3maxacalcitolIBA
04/2006 - 12/2003
3EnzymesIBA
12/2005 - 03/2002
3P-SelectinIBA
05/2005 - 08/2003
3hydroxide ionIBA
04/2005 - 01/2002

Therapy/Procedure

56Renal Dialysis (Hemodialysis)
12/2018 - 09/2001
18Therapeutics
02/2017 - 03/2003
6Glycemic Control
10/2012 - 03/2005
4Blood Component Removal (Apheresis)
02/2022 - 08/2006